MSF in HIV
Doctors Without Borders/Medécins Sans Frontières (MSF) has been caring for people living with HIV/AIDS since the mid-1990s, while campaigning with partners to remove barriers to affordable, quality HIV treatment for all.
Today, MSF supports HIV treatment for 250,000 people in 19 countries throughout Africa, Asia and Eastern Europe.
While our programmes offer HIV care the implementation models we’ve developed and our field experience offer unique insights into improving practice that ensures the HIV response is in step with the reality of people on treatment. We continue to push for access to newer, more affordable treatment and diagnostic technologies for HIV/AIDS and TB.
At the historic AIDS2016, MSF will share operational research related to simplified patient-focused differentiated models of care, linkage and retention in care, human resources for health as well as scale up of routine viral load monitoring.
Our staff will share the field realities from countries in West and Central Africa, as well as conflict affected contexts where life-saving antiretroviral therapy (ART) coverage is alarmingly low.
MSF will also provide the latest reporting on drug pricing trends and threats to affordable access to HIV treatment.
Follow @MSF_HIV for regular updates & live coverage during AIDS2016.
HIV Drug Price Reductions – MSF untangles the web
New Threats to Treatment Access: MSF launches all new ‘Untangling The Web’ report
Now in its 18th edition, ‘Untangling the Web of Antiretroviral Price Reductions’ provides a comprehensive overview of pricing for first-, second-line and salvage regimens of HIV drugs. The report analyses trends in pricing and examines multiple global threats to access to affordable treatment, including trade deals which jeopardizes India’s role as the ‘pharmacy of the developing world.’
MSF@AIDS 2016 Abstracts
MSF implemented 3 modalities of HIV testing in uThungulu District, beginning 2012: fixed sites (FS), mobile sites (MS), and door-to-door (D2D). An ingredients approach was used to analyse costs associated with these testing modalities for 2014. Client structures were analysed for men and women 15 to 59 years of age, for each testing modality, and compared to those of health facilities (HF).